Goldman Sachs
OTLK icon

Goldman Sachs’s Outlook Therapeutics OTLK Stock Holding History

Goldman Sachs’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,275
Closed -$2.12K – 6872
2026
Q1 		$2.12K Sell
10,275
-35,507
-78% -$15.3K ﹤0.01% 6419
2025
Q4 		$72.3K Buy
45,782
+2,812
+7% +$4.49K ﹤0.01% 6245
2025
Q3 		$45.5K Sell
42,970
-49,398
-53% -$85.4K ﹤0.01% 6181
2025
Q2 		$148K Sell
92,368
-11,156
-11% -$17.8K ﹤0.01% 5741
2025
Q1 		$126K Buy
103,524
+44,063
+74% +$77.3K ﹤0.01% 5738
2024
Q4 		$112K Buy
59,461
+23,887
+67% +$98.3K ﹤0.01% 5745
2024
Q3 		$190K Buy
+35,574
New +$260K ﹤0.01% 5472
2024
Q1 		– Sell
-2,767
Closed -$21.8K – 5789
2023
Q4 		$21.8K Sell
2,767
-295
-10% -$2.49K ﹤0.01% 5440
2023
Q3 		$13.5K Sell
3,062
-3,569
-54% -$79K ﹤0.01% 5386
2023
Q2 		$231K Buy
6,631
+3,080
+87% +$84K ﹤0.01% 5126
2023
Q1 		$77.4K Sell
3,551
-5,826
-62% -$130K ﹤0.01% 5491
2022
Q4 		$203K Buy
9,377
+4,643
+98% +$101K ﹤0.01% 5302
2022
Q3 		$115K Sell
4,734
-529
-10% -$12.3K ﹤0.01% 5653
2022
Q2 		$107K Sell
5,263
-1,643
-24% -$47.2K ﹤0.01% 5840
2022
Q1 		$246K Buy
6,906
+1,340
+24% +$41.8K ﹤0.01% 5769
2021
Q4 		$152K Sell
5,566
-1,990
-26% -$71K ﹤0.01% 6002
2021
Q3 		$328K Buy
7,556
+7,027
+1,328% +$339K ﹤0.01% 5441
2021
Q2 		$26K Sell
529
-3,785
-88% -$176K ﹤0.01% 6130
2021
Q1 		$194K Buy
4,314
+2,023
+88% +$77.5K ﹤0.01% 5659
2020
Q4 		$60K Sell
2,291
-1,575
-41% -$32.9K ﹤0.01% 5357
2020
Q3 		$56K Buy
+3,866
New +$86.2K ﹤0.01% 5174
2017
Q1 		– Sell
-811
Closed -$390K – 6932
2016
Q4 		$390K Sell
811
-6
-0.7% -$3.36K ﹤0.01% 5274
2016
Q3 		$555K Buy
+817
New +$519K ﹤0.01% 4944

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Goldman Sachs's OTLK Position: Q2 2026 in Review

Goldman Sachs sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 10,275 shares — an estimated $2.12K sold.

Goldman Sachs first reported a position in OTLK in Q3 2016 and held it in 23 quarters. The position peaked at $555K in Q3 2016. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Goldman Sachs reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 10,275 Outlook Therapeutics shares in Q2 2026, an estimated $2.12K.
  • Goldman Sachs first reported a position in Outlook Therapeutics in Q3 2016 and held it in 23 quarters.
  • Goldman Sachs's Outlook Therapeutics position peaked at $555K in Q3 2016.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.